Arrowhead prices offering at $104M; FDA clears rectal delivery device from Hospi;

> Arrowhead ($ARWR) priced an underwritten offering of 5.5 million shares at $18.95 per share. The RNAi therapeutic company expects to pull in about $104 million. Release

> The FDA cleared Hospi Corporation's Macy Catheter device for rectal administration of liquid medication. More

The Wall Street Journal highlighted Mir Imran's Rani Therapeutics, which, backed by Google ($GOOG), is developing a robotic pill to replace injections. Profile

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.